| Literature DB >> 30712951 |
A Moruno-Rodríguez1, J L Sánchez-Vicente2, T Rueda-Rueda3, B Lechón-Caballero3, A Muñoz-Morales4, F López-Herrero5.
Abstract
A 30 year-old man with acute myeloblastic leukaemia and secondary myelodysplastic syndrome developed graft-versus-host disease. The patient was treated with ruxolitinib. After being treated for 3 months with ruxolitinib, an inhibitor of Janus kinase, he developed Aspergillus retinal necrosis resistant to common treatment. Treatment with Janus kinase inhibitors may lead to an increased incidence of opportunistic infections. Janus kinase inhibitor administration may result in poor treatment efficacy.Entities:
Keywords: Acute myeloblastic leukaemia; Aspergillus; Enfermedad injerto contra huésped; Graft-versus-host disease; Leucemia mieloblástica aguda; Myelodysplastic syndrome; Necrosis retiniana; Retinal necrosis; Ruxolitinib; Síndrome mielodisplásico
Mesh：
Substances：
Year: 2019 PMID： 30712951 DOI： 10.1016/j.oftal.2018.12.006
Source DB: PubMed Journal: Arch Soc Esp Oftalmol (Engl Ed) ISSN： 2173-5794